{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:33:51Z","timestamp":1791178431683,"version":"4.1.0"},"reference-count":24,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2003,8]]},"abstract":"<jats:p> We have explored the therapeuticpotentialof statins in patients with differentinflammatory rheumatic diseases refractory to conventional therapy. We found that simvastatin (80mg o.d. for eight days) induced a rapid and significant reduction in proteinuria levels in three systemic lupus erythematosus (SLE) patients. A similar kind of therapy had a marked beneficial effect in a patient with Wegener\u2019s granulomatosis and a patient with erythema nodosum. On the other hand, five patients with rheumatoid arthritis (RA) who received atorvastatin for eight days (20mg\/day) showed reduction in C-reactive protein levels and a clinical improvement that was classified as an ACR20 response. Prior to the administrationof statins, all these patients had receivedaggressiveconventionaltherapy with no satisfactory response. A significant reduction in spontaneous apoptosis of peripheral blood lymphocytes and expression of CD69 and HLA-DR was observed in SLE patients after simvastatin therapy. These results prompted us to perform a pilot short-time comparative (simvastatin versus chloroquine) open clinical trial in 15 patients with RA who were receiving methotrexate as a single disease modifying antirheumatic drug with no satisfactory response. Most patients (9\/10) who received simvastatin (40mg\/day) showed an ACR50 or better response after eight weeks, whereas such a response was not observed in any patient (0\/5) treated with chloroquine. Our preliminary results indicate that statins may be an important therapeutic tool for the treatment of inflammatory rheumatic diseases. <\/jats:p>","DOI":"10.1191\/0961203303lu429oa","type":"journal-article","created":{"date-parts":[[2003,11,12]],"date-time":"2003-11-12T12:45:16Z","timestamp":1068641116000},"page":"607-611","source":"Crossref","is-referenced-by-count":97,"title":["Therapy with statins in patients with refractory rheumatic diseases: a                 preliminary study"],"prefix":"10.1177","volume":"12","author":[{"given":"C","family":"Abud-Mendoza","sequence":"first","affiliation":[{"name":"Unidad Regional de Reumatolog\u00eda y Osteoporosis, Hospital                         Central, San Luis Potos\u00ed, Mexico, Departamento de                         Inmunolog\u00eda Facultad de Medicina, Universidad Aut\u00f3noma                         de San Luis Potos\u00ed, San Luis Potos\u00ed, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"de la Fuente","sequence":"additional","affiliation":[{"name":"Departamento de Inmunolog\u00eda Facultad de Medicina, Universidad                         Aut\u00f3noma de San Luis Potos\u00ed, San Luis                         Potos\u00ed, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Cuevas-Orta","sequence":"additional","affiliation":[{"name":"Unidad Regional de Reumatolog\u00eda y Osteoporosis, Hospital                         Central, San Luis Potos\u00ed, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Baranda","sequence":"additional","affiliation":[{"name":"Departamento de Inmunolog\u00eda Facultad de Medicina, Universidad                         Aut\u00f3noma de San Luis Potos\u00ed, San Luis                         Potos\u00ed, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cruz-Rizo","sequence":"additional","affiliation":[{"name":"Unidad Regional de Reumatolog\u00eda y Osteoporosis, Hospital                         Central, San Luis Potos\u00ed, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gonz\u00e1lez-Amaro","sequence":"additional","affiliation":[{"name":"Departamento de Inmunolog\u00eda Facultad de Medicina, Universidad                         Aut\u00f3noma de San Luis Potos\u00ed, San Luis                         Potos\u00ed, M\u00e9xico,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2003,8,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1038\/82107"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1038\/82219"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00870-0"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(00)00439-3"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1038\/89058"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780115"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.1.64"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.15.1933"},{"key":"atypb9","first-page":"41","volume":"131","author":"Kwak B","year":"2001","journal-title":"Schweiz Med Wochenschr"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01400-4"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.83.5.490"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1191\/096120301666117984"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360601"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600107"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119806"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(86)80165-2"},{"key":"atypb17","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1681\/ASN.V9112027","volume":"9","author":"Yoshimura A","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00332.x"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00304.x"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2423(03)37009-X"},{"key":"atypb21","volume-title":"Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy","author":"Sanjad SA"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1524"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199809000-00016"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00272-1"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/0961203303lu429oa","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/0961203303lu429oa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:27:34Z","timestamp":1740788854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1191\/0961203303lu429oa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["10.1191\/0961203303lu429oa"],"URL":"https:\/\/doi.org\/10.1191\/0961203303lu429oa","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}